Drug-diagnostic co-development: how to harness the value

Area of Science:

• Health economics and outcomes research
• Pharmaceutical market analysis
• Drug valuation methodologies

Background:

• A prior value assessment process was established based on assumptions linking drug development and marketing to valuation.
• Significant shifts in regulatory policies and reimbursement strategies have occurred since the process was developed.

Purpose of the Study:

• To evaluate the continued validity of the initial assumptions in the value assessment process.
• To examine the impact of regulatory and reimbursement changes on drug valuation.
• To test and stratify recent cases using derived relationship models.

Main Methods:

• Review of historical assumptions in drug valuation.
• Analysis of current regulatory and reimbursement environments.
• Empirical testing of relationship models through case studies involving testing and stratification.

Main Results:

• The study assesses how the initial assumptions of the drug valuation process have performed under new market conditions.
• The relationship models derived from the value assessment process were substantiated through recent case analyses.
• The findings provide insights into the robustness of the valuation framework amidst industry changes.

Conclusions:

• The established drug valuation framework demonstrates resilience and adaptability.
• Regulatory and reimbursement shifts necessitate ongoing refinement of valuation models.
• The study validates the utility of the developed models for current pharmaceutical market assessment.